{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreich32z45ijos4mveoaa2citdq6ydskk2wneqomncryknnw4j337xe",
    "uri": "at://did:plc:5ka4qkui7nvjms7idhte2m4o/app.bsky.feed.post/3mluls6c4qxw2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreihs4yniv5gslv4xxwpwazmdqvpsj3sble4olz6hvbzdguafle3ihy"
    },
    "mimeType": "image/jpeg",
    "size": 123080
  },
  "path": "/pharmalot/2026/05/14/biogen-regenxbio-report-results-for-alzheimers-duchenne-takeda-layoffs/?utm_campaign=rss",
  "publishedAt": "2026-05-14T13:44:43.000Z",
  "site": "https://www.statnews.com",
  "tags": [
    "Pharma",
    "Pharmalot",
    "pharmalittle",
    "STAT+"
  ],
  "textContent": "Biogen reported mixed results from a mid-stage clinical trial investigating a treatment for Alzheimer’s disease that targets the protein tau",
  "title": "STAT+: Pharmalittle: We’re reading about upbeat results for a Duchenne drug, Takeda layoffs, and much more",
  "updatedAt": "2026-05-14T13:44:48.000Z"
}